Kyushu University Academic Staff Educational and Research Activities Database
Search by Keyword How ro search
Keyword
Search Criteria
 
Detailed Search

List of Papers
Isamu Okamoto Last modified date：2023.11.22

Professor / Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University / Department of Clinical Medicine / Faculty of Medical Sciences


Papers
1. Otsubo K., Kishimoto J., Ando M., Kenmotsu H., Minegishi Y., Horinouchi H., Kato T., Ichihara E., Kondo M., Atagi S., Tamiya M., Ikeda S., Harada T., Takemoto S., Hayashi H., Nakatomi K., Kimura Y., Kondoh Y., Kusumoto M., Ichikado K., Yamamoto N., Nakagawa K., Nakanishi Y. & Okamoto I. , Nintedanib plus chemotherapy for non–small cell lung cancer with IPF: a randomized phase 3 trial, European Respiratory Journal , 10.1183/13993003.00380-2022, 60(6), 2022.12, 背景
特発性肺線維症（IPF）は肺癌の独立した危険因子として関与している致死的な肺疾患である。しかし、IPF進行肺がんに対する最適な治療法は確立されていない。我々はIPFを有する進行性非小細胞肺がん（NSCLC）に対するニンテダニブ＋化学療法（実験群）と化学療法単独（標準治療群）の有効性と安全性を評価する無作為化第3相試験（J-SONIC）を実施しました。

方法
IPFを有する化学療法未実施の進行NSCLC患者を、カルボプラチン＋ナノ粒子アルブミン結合パクリタキセル（nab-paclitaxel）の3週間ごとの投与とニンテダニブ（150mg1日2回、毎日）の併用、非併用を割り振った。主要評価項目はIPF無増悪生存期間（EFS）であった。

結果：
2017年5月から2020年2月にかけて、243人の患者が登録された。IPF無増悪生存期間中央値はニンテダニブ＋化学療法群で14.6カ月、化学療法群で11.8カ月（ハザード比（HR）0.89、90％CI 0.67-1.17、p＝0.24）、一方無増悪生存期間中央値はそれぞれ6.2カ月と5.5カ月（HR 0.68 、95％CI 0.50-0.92 ）でした。全生存期間は、非扁平上皮組織（HR 0.61、95% CI 0.40-0.93）およびGAPステージIの患者において、ニンテダニブにより改善した（HR 0.61, 95% CI 0.38-0.98 ）。240人中7人（2.9%）が試験治療中にIPFの急性増悪を経験した。

結論
本試験の主要評価項目は達成されなかった。しかし、カルボプラチン＋nab-パクリタキセルは、IPFを有する進行NSCLC患者において有効かつ忍容性があることが判明した。さらに、ニンテダニブとこのような化学療法を併用することで、非扁平上皮組織型の患者の全生存期間が改善された。.
2. Tsutsumi H., Iwama E., Ibusuki R., Shimauchi A., Ota K., Yoneshima Y., Inoue H., Tanaka K., Nakanishi Y. & Okamoto I. , Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers, Lung Cancer , 175, 101-111 , 2023.01.
3. Tanaka K., Chamoto K., Saeki S., Hatae R., Ikematsu Y., Sakai K., Ando N., Sonomura K., Kojima S., Taketsuna M., Hak Kim Y., Yoshida H., Ozasa H., Sakamori Y., Hirano T., Matsuda F., HiraiT., Nishio K., Sakagami T., Fukushima M., Nakanishi Y., HonjoT. & Okamoto I. , Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer, Science Translational Medicine, 14(675),eabq0021 , 2022.12.
4. Shiraishi Y., Shimose T., Tsuchiya-Kawano Y., Ishii H., Daga H., Ito K., Saruwatari K. & Okamoto I., Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases

, Cancer Management and Research , 14, 3449-3453, 2022.12.
5. Okamura K., Inoue H., Tanaka K., Ikematsu Y., Furukawa R., Ota K., Yoneshima Y., Iwama E. & Okamoto I., Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma, Cancer Science, 114(3), 1095-1107, 2022.11.
6. Ibusuki R., Yoneshima Y., Hashisako M., Matsuo N., Harada T., Tsuchiya-Kawano Y., Kishimoto J., Ota K., Shiraishi Y., Iwama E., Tanaka K., Oda Y. & Okamoto I. , Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer, Translational Lung Cancer Research , 11(11), 2208-2215 , 2022.12.
7. Shiraishi Y., Kishimoto J., Shimose T., Toi Y., Sugawara S. & Okamoto I. , Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial, BMC Cancer , 22(1), 964, 2022.12.
8. Yoneshima Y., Morita S., Ando M., Nakamura A., Iwasawa S., Yoshioka H., Goto Y., Takeshita M., Harada T., Hirano K., Oguri T., Kondo M., Miura S., Hosomi Y., Kato T., Kubo T., Kishimoto J., Yamamoto N., Nakanishi Y. & Okamoto I., Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment, Clinical Lung Cancer, 23(7), 585-592, 2022.11.
9. Izumi H., Matsumoto S., Liu J., Tanaka K. Mori S., Hayashi K., Kumagai S., Shibata Y., Hayashida T., Watanabe K., Fukuhara T., Ikeda T., Yoh K., Kato T., Nishino K., Nakamura A., Nakachi I., Kuyama S., Furuya N., Sakakibara – Konishi J., Okamoto I., Taima K., Ebi N., Daga H., Yamasaki A., Kodani M., Udagawa H., Kirita K., Zenke Y., Nosaki K., Sugiyama E., Sakai T., Nakai T., Ishii G., Niho S., Ohtsu A., Kobayashi S. & Goto K. , The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer, Nature , 600(7888), 319-3239, 2021.12.
10. Iwama E., Zenke Y., Sugawara S., Daga H., Morise M., Yanagitani N., Sakamoto T., Murakami H., Kishimoto J., Matsumoto S., Nakanishi Y., Goto K. & Okamoto I., Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations

, European Journal of Cancer, 162, 99-106, 2022.02, 【Background】“Cancer genomic medicine” for development of an innovative medicines based on the analysis of information about genomics and clinical records is now ongoing in Japan. It is expected that introduction of the comprehensive genomic analysis and screening of cancer-related gene are going to be carried on a full-scale operation in the near future. Although HER2 gene mutations are one of the driver mutations and have been identified in 2-4% of non-small cell lung cancer (NSCLC), no effective targeted therapy has been developed for NSCLC with such mutations. Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate of trastuzumab and derivative of maytansine (DM1), which has been approved for metastatic breast cancer positive for overexpression of HER2 protein but not for NSCLC. It has recently been reported that T-DM1 demonstrated a marked ORR of 44% (8 of 18 patients) in a phase II study abroad. Moreover, the ORR was 55% (6 of 11 patients) when focused on the exon 20 insertion mutation including exon 20 A775_G776insYVMA, which accounts for most (50-96%) of HER2 mutations. Several retrospective studies have shown that ORR in treatment with combination therapy of trastuzumab and chemotherapy for patients with NSCLC positive for HER2 exon 20 insertion mutations was 50-60%. Together with the basic studies demonstrating that HER2 exon 20 insertion mutations have functions as a driver mutation, such mutations should be a good target for treatment with an anti-HER antibody.

【Method】We have planned to conduct a phase II study to evaluate the efficacy of T-DM1 for NSCLC positive for HER2 exon 20 insertion mutations (target sample size: 20), with ORR being a primary endpoint and with progression free survival, overall survival and safety being secondary endpoints. NSCLC with such mutations will be screened based on a next generation sequencing based comprehensive genomic profiling assay of FoundationOne CDxTM, LC-SCRUM-Japan or NCC Oncopanel. The purpose of our study is to have T-DM1 approved in expanded use for NSCLC positive for HER2 exon 20 insertion mutations, which confer an appropriate molecular targeted therapy to patients harboring such disease who have only received a treatment based on cytotoxic drugs.

【Results】Between February 2019 and July 2020, 22 patients were enrolled in the study. A775_G776insYVMA was the most frequent HER2 exon-20 insertion mutation, accounting for 19 (86.4%) of the 22 patients. The ORR was 38.1% (90% confidence interval, 23.0-55.9%), and the disease control rate was 52.4%. The median duration of response was 3.5 months, and the median progression-free survival and median overall survival were 2.8 and 8.1 months, respectively. Toxicity was mild, with the frequency of adverse events of grade 3 or more being low.

【Conclusion and significance】Although these findings did not result in an approval of T-DM1 for NSCLC with HER2 exon-20 insertion mutations in Japan, our study demonstrated the similar effectiveness to that observed in the previous study, confirming the treatment strategy of anti-HER2 antibody-drug conjugate for such disease..
11. Shiraishi Y., Hakozaki T., Nomura S., Kataoka T., Tanaka K., Miura S., Sekino Y., Ando M., Horinouchi H., Ohe Y. & Okamoto I., A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

, Clinical Lung Cancer , 23(4), e285 - e288, 2021.10.
12. Tsuchiya-Kawano Y., Shiraishi Y., Kiyomi F. & Okamoto I. , Phase ii study of nivolumab plus ipilimumab with platinum-based chemotherapy for treatment-naïve advanced non-small cell lung cancer with untreated brain metastases: Nike trial (logik2004), Cancer Management and Research, 13, 8489–8493, 2021.11.
13. Yoneshima Y, Iwama E, Matsumoto S, Matsubara T, Tagawa T, Ota K, Tanaka K, Takenoyama M, Okamoto T, Goto K, Mori M, Okamoto I. , Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis., Scientific Reports , 11(1), 12732, 2021.07.
14. Liu R., Ota K., Iwama E., Yoneshima Y., Tanaka K., Inoue H., Tagawa T., Oda Y., Mori M., Nakanishi Y. & Okamoto I. , Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib, Lung Cancer , 158, 156-161 , 2021.08.
15. Furukawa R., Inoue H., Yoneshima Y., Tsutsumi H., Iwama E., Ikematsu Y., Ando N., Shiraishi Y., Ota K., Tanaka K., Nakanishi Y. & Okamoto I. , Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer, Lung Cancer , 155, 144-150
, 2021.05.
16. Inoue H., Tsutsumi H., Tanaka K., Iwama E, Shiraishi Y., Hirayama A., Nakanishi T., Ando H., Nakajima M., Shinozaki S., Ogata H., Uryu K., Okamura K., Kimura S., Ogawa T., Ota K., Yoneshima Y, Hamada N., Nakanishi Y. & Okamoto I. , Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer , Translational Lung Cancer Research , 10(6), 2475-2486, 2021.06.
17. Tanaka K., Asahina H., Kishimoto J., Miyata Y, Uchida T., Watanabe K., Hamai K., Harada T., Tsubata Y., Sugawara S., Kobayashi K., Sugio K., Oisumi S. & Okamoto I. , Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial, European Journal of Cancer , 149, 14-22 , 2021.05.
18. Satouchi M., Nosaki K., Takahashi T. Nakagawa K., Aoe K., Kurata T., Sekine A., Horiike A., Fukuhara T., Sugawara S., Umemura S., Saka H., Okamoto I., Yamamoto N., Sakai, H., Kishi K., Katakami N., Horinouchi H., Hida T., Okamoto H., Atagi S., Ohira T., Han Shi Rong, Noguchi K., Ebiana V. & Hotta K.　, First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset

, Cancer Science, 2021.09.
19. Matsukane R., Watanabe H., Hata K., Suetsugu K., Tsuji T., Egashira N., Nakanishi Y., Okamoto I. & Ieiri I. , Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy.
, Scientific Reports , 11(1), 15057 , 2021.07.
20. Yu HA., Goldberg SB., Le X., Piotrowska Z., Goldman JW., De Langen AJ., Okamoto I., Cho BC., Smith P., Mensi I., Ambrose H., Kraljevic S., Maidment J., Chmielecki J., Li-Sucholeiki X., Doughton G., Patel G., Jewsbury P., Szekeres P. & Riess JW., Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

, Clinical Lung Cancer , 2021.06.
21. Johnson ML., Zvirbule Z., Laktionov K., Helland A., Cho BC., Gutierrez V., Colinet B., Lena H., Wolf M., Gottfried M., Okamoto I., Leest C., Rich P., Hung JY., Appenzeller C., Zhaowen S., Maag D., Luo Y., Nickner C., Vajikova A., Komarnitsky P. & Bar J. , Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study, Journal of Thoracic Oncology , 16(9), 1570-1581, 2021.09.
22. Takada K., Shimokawa M., Takamori S., Shimamatsu S., Hirai F., Tagawa T., Okamoto T., Hamatake M., Tsuchiya Y., Otsubo K., Inoue K., Yoneshima Y., Tanaka K., Okamoto I., Nakanishi Y. & Mori M. , Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting, International Journal of Cancer , 149(2), 473-482, 2021.07.
23. Hotta K., Nishio M., Saito H., Okamoto I., Nakahara Y., Hayashi H., Hayama M., Laud P., Jiang H., Paz-Ares L. & Azuma K. , First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis.
, International Journal of Clinical Oncology , 26(6), 1073-1082 , 2021.06.
24. Takeda M., Shimokawa M., Nakamura A., Nosaki K., Watanabe Y., Kato T., Hayakawa D., Tanaka H., Takahashi T., Oki M. Tachihara M., Fujimoto D., Yamaguchi K., Nogami N., Okamoto I., Azuma K., Hasegawa K., Yamamoto N. & Nakagawa K. , A Phase II Study of Osimertinib in EGFR¬-Mutated Non–Small Cell Lung Cancer Patients with Isolated Central Nervous System Progression (EGFR-T790M Negative or Unknown) after First- or Second-Generation Tyrosine Kinase Inhibitor Therapy or with Systemic Disease Progression (T790M Negative) after both such Treatment and Platinum-Based Chemotherapy (WJOG12819L), Clinical Lung Cancer , 22(4), 376-380, 2021.07.
25. Takamori S., Takada K., Shimokawa M., Jinnouchi M., Matsubara T., Haratake N., Miura N., Toyozawa R., Yamaguchi M., Takenoyama M., Yoneshima Y., Tanaka K., Okamoto I., Tagawa T. & Mori M. , Prognostic impact of primary cancer adjoining emphysematous bullae in non-small-cell lung cancer patients treated with immune checkpoint inhibitors., Cancer Immunology Immunotherapy , 70(6), 1745-1753, 2021.06.
26. Blackhall F., Jao K., Greillier L., Cho BC., Penkov K., Reguart N., Majem M., Nackaerts K., Syrigos K., Hansen K., Schuette W., Cetnar J., Cappuzzo F., Okamoto I., Erman M., Langer SW., Kato T., Groen H., Sun Z., Luo Y., Tanwani P., Caffrey L., Komarnitsky P. & Reinmuth N., Efficacy and Safety of Rovalpituzumab Tesirine as Second-Line Therapy in DLL3-High Small-Cell Lung Cancer: Results from the Phase 3 TAHOE Study, Journal of Thoracic Oncology, 16(9), 1547-1558, 2021.09.
27. Takamori S., Takada K., Shimokawa M., Matsubara T., Fujishita T., Ito K., Toyozawa R., Yamaguchi M., Okamoto T., Yoneshima Y., Tanaka K., Okamoto I., Tagawa T. & Mori M. , Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors, Lung Cancer, 152, 27-33, 2021.02.
28. Asahina H., Tanaka K., Morita S., Maemondo M., Seike M., Okamoto I., Oizumi S., Kagamu H., Takahashi K., Kikuchi T., Isobe T., Sugio K. & Kobayashi K., A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced NoneSmall-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801), Clinical Lung Cancer, 22(2), 147-151, 2021.03.
29. Yamamoto N., Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Yamanaka T., Tanaka M., Takahashi K. & Fukuoka M. , Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study, Lung Cancer , 151, 20-24 , 2021.01.
30. Sakai K., Takahama T., Shimokawa M., Azuma K., Takeda M., Kato T., Daga H., Okamoto I., Akamatsu H., Teraoka S., Ono A., Ohira T., Yokoyama T., Yamamoto N., Nakagawa K. & Nishio K. , Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L)., Molecular Oncology , 15(1), 126-137 , 2021.01.
31. Matsukane R., Watanabe H.., Minami H, Hata K., Suetsugu K., Tsuji T., Masuda S., Okamoto I., Nakagawa T., Ito T., Eto M., Mori M., Nakanishi Y. & Egashira N. , Continuous monitoring of neutrophils to lymphocytes ratio for estimation of onset and severity of immune-related adverse events and prognosis, Scientific Reports , 11(1), 1324, 2021.01.
32. Yamamoto N., Harada H., Okamoto I., Masuda N.., Hayakawa K, Satouchi M., Soejima T., Nishio M., Kozuka T., Takeda K., Tanaka M., Seto T., Sasaki T., Tsubouchi H., Kakurai Y., Nishimura Y. & Nakagawa K., Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced NoneSmall-Cell Lung Cancer, Clinical Lung Cancer, 22(2), 134-141 , 2021.03.
33. Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I, Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC, Journal of Thoracic Oncology, 2021.04, Introduction: We aimed to assess the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced non-small cell lung cancer (NSCLC).
Methods: In this randomized, open-label, noninferiority phase 3 trial, we enrolled patients with advanced NSCLC previously treated with cytotoxic chemotherapy. Patients were randomly allocated (1:1) to receive docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 mg/m2) on days 1, 8, and 15 of a 21-day cycle. The primary end point was overall survival analyzed on an intention-to-treat basis.
Results: Between 22 May 2015 and 12 March 2018, 503 patients were randomly allocated to treatment. Median overall survival was 16.2 months (95% CI, 14.4-19.0) for the 252 patients allocated to nab-paclitaxel and 13.6 months (95% CI, 10.9-16.5) for the 251 patients allocated to docetaxel (hazard ratio, 0.85; 95.2% CI, 0.68-1.07). Median progression-free survival was 4.2 months (95% CI, 3.9-5.0) for the nab-paclitaxel group versus 3.4 months (95% CI, 2.9-4.1) for the docetaxel group (hazard ratio, 0.76; 95% CI, 0.63-0.92; p=0.0042). The objective response rate was 29.9% (95% CI, 24.0-36.2) for the nab-paclitaxel group and 15.4% (95% CI, 10.9-20.7) for the docetaxel group (p=0.0002), and it showed a significant improvement for nab-paclitaxel versus docetaxel regardless of tumor histology. Adverse events of grade ≥3 included febrile neutropenia (5 [2%] of 245 patients in the nab-paclitaxel group versus 55 [22%] of 249 patients in the docetaxel group) and peripheral sensory neuropathy (24 [10%] versus 2 [1%], respectively).
Conclusions: Nab-paclitaxel was noninferior to docetaxel in terms of overall survival. It should thus be considered a standard treatment option for previously treated patients with advanced NSCLC..
34. Ikeda S., Kato T., Kenmotsu H., Ogura T., Iwasawa S., Sato Y., Harada T., Kubota K., Tokito T., Okamoto I., Furuya N., Yokoyama T., Hosokawa S., Iwasawa T., Yamanaka T. & Okamoto H. , A phase 2 study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonitis
, Journal of Thoracic Oncology , 15(12), 1935-1942, 2020.12.
35. Satouchi M., Nosaki K., Takahashi T., Nakagawa K., Aoe K., Kurata T., Sekine A., Horiike A., Fukuhara T., Sugawara S., Umemura S., Saka H., Okamoto I., Yamamoto N., Sakai H., Kishi K., Katakami N., Horinouchi H., Hida T., Okamoto H., Atagi S., Ohira T., Han SR., Noguchi K., Ebiana V. & Hotta K. , First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset., Cancer Science , 111(12), 4480-4489, 2020.12.
36. Okishio K., Morita R., Shimizu J., Saito H., Sakai H., Kim YH., Hataji O., Yomota M., Nishio M., Aoe K., Kanai O., Kumagai T., Kibata K., Tsukamoto H., Oizumi S., Fujimoto D., Tanaka H., Mizuno K., Masuda T., Kozuki T., Haku T., Suzuki H., Okamoto I., Hoshiyama H., Yada N. & Ohe Y. , Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study., ESMO Open, 4, e000656., 2020.12.
37. Shimizu T., Nishio K., Sakai K., Okamoto I., Okamoto K., Takeda M., Morishima M. & Nakagawa K. , Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small-cell lung cancer, Cancer Chemotherapy and Pharmacology , 86(2), 211-219 , 2020.08.
38. Paz-Ares L., Vicente D., Tafreshi A., Robinson A., Parra HS., Marieres J., Hermes B., Cicin I., Medgyasszay B., Cid JR., Okamoto I., Lee S., Ramlau R., Vladimirov V., Cheng Y., Deng X., Zhang Y., Bas T., Piperdi B. & Halmos B. , A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung , Journal of Thoracic Oncology , 15(10), 1657-1669 , 2020.10.
39. Takada K., Toyokawa G., Kinoshita F., Jogo T., Kohashi K., Wakasu S., Ono Y., Tanaka K., Oba T., Osoegawa A., Tagawa T., Azuma K., Okamoto I., Shimokawa M., Oda Y. & Mori M. , Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype, Journal of Cancer Research and Clinical Oncology , 146(10), 2639-2650, 2020.10.
40. Takamori S., Takada K., Shimokawa M., Matsubara T., Haratake N., Miura N., Toyozawa R., Yamaguchi M., Takenoyama M., Yoneshima Y, Tanaka K., Okamoto I., Tagawa T. & Mori M. , Predictive and prognostic impact of primary tumor-bearing lobe in non-small cell lung cancer patients treated with anti-PD-1 therapy, International Journal of Cancer , 147(8), 2327-2334, 2020.10.
41. Suzuki K., Yanagihara T., Matsumoto K., Kusaba H., Yamaguchi T., Ikematsu Y., Tanaka K., Otsubo K., Inoue H., Yoneshima Y, Iwama E., Arimura-Omori M., Harada E., Hamada N., Okamoto I. & Nakanishi Y. , Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitorrelated interstitial lung disease, International Immunology , 32(8), 547-557 , 2020.08.
42. Wakuda K., Yamaguchi H., Kenmotsu H., Fukuda M., Takeshita M., Suetsugu T., Kirita K., Ebi N., Hataji O., Miura S., Chibana K., Okamoto I., Yoshimura K., Nakagawa K., Yamamoto N. & Sugio K. , A Phase II Study of Osimertinib for Patients with Radiotherapy-naïve CNS Metastasis of Non-Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the　OCEAN Study (LOGIK 1603/WJOG 9116L), BMC Cancer , 20(1), 370 , 2020.12.
43. Tokudome N., Koh Y., Akamatsu H., Fujimoto D., Okamoto I., Nakagawa K., Hida T., Imamura F., Morita S. & Yamamoto N. , Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy, BMC Cancer, 20(1), 103, 2020.12.
44. Sekine I., Shintani Y., Shukuya T., Takayama K., Inoue A., Okamoto I., Kiura K., Takahashi K., Dosaka-Akita H., Takiguchi Y., Miyaoka E., Okumura M. & Yoshino I. , A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients, Cancer Science , 111(5), 1685-1691, 2020.05.
45. Kobayashi K., Soejima K., Fukunaga K., Shintani Y., Sekine I., Shukuya T., Takayama K., Inoue A., Okamoto I., Kiura K., Takahashi K., Yamamoto N., Takiguchi Y., Miyaoka E., Okumura M. & Yoshino I. , Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database, Lung Cancer, 146, 236-243, 2020.08.
46. Igawa S., Naoki K., Shintani Y., Sekine I., Shukuya T., Takayama K., Inoue A., Okamoto I., Kiura K., Takahashi K., Yamamoto N., Takiguchi Y., Miyaoka E., Okumura M. & Yoshino I. , Survival and Prognostic Factors in Elderly Patients Receiving Second-line Chemotherapy for Relapsed Small-Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry, Lung Cancer , 146, 160-164 , 2020.08.
47. Takada K., Takamori S., Yoneshima Y., Tanaka K., Okamoto I., Shimokawa M., Osoegawa A., Tagawa T., Oda Y., Nakanishi Y. & Mori M. , Serum markers associated with treatment 1 response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy, Lung Cancer , 145, 18-26 , 2020.07.
48. Morita R., Okishio K., Shimizu J., Saito H., Sakai H., Kim YH., Hataji O., Yomota M., Nishio M., Aoe K., Kanai O., Kumagai T., Kibata K., Tsukamoto H., Oizumi S., Fujimoto D., Tanaka H., Mizuno K., Masuda T., Kozuki T., Haku T., Suzuki H., Okamoto I., Hoshiyama H., Ueda J. & Ohe Y. , Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. , Lung Cancer , 140, 8-18 , 2020.02.
49. Takahama T., Azuma K., Shimokawa M., Takeda M., Ishii H., Kato T., Saito H., Daga H., Tsuboguchi Y., Okamoto I., Otsubo K., Akamatsu H., Teraoka S., Takahashi T., Ono A., Ohira T., Yokoyama T., Sakai K., Yamamoto N., Nishio K. & Nakagawa K. , Plasma screening for the T790M mutation of EGFR and phase II study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group (WJOG) 8815L/LPS study. , Cancer 126(9) , 1940-1948, 2020.05.
50. Kenmotsu H., Yamamoto N., Yamanaka T., Yoshiya K., Takahashi T., Ueno T., Goto K., Daga H., Ikeda N., Sugio K, Seto T., Toyooka S., Date H., Mitsudomi T., Okamoto I., Yokoi K., Saka H., Okamoto H., Takiguchi Y. & Tsuboi M. , Randomized Phase III Study of Cisplatin Plus Pemetrexed Versus Cisplatin Plus Vinorelbine for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer, Journal of Clinical Oncology , 38(19), 2187-2196 , 2020.07.
51. Seto T., Azuma K., Yamanaka T., Sugawara S., Yoshioka H., Wakuda K., Atagi S., Iwamoto Y., Hayashi H., Okamoto I., Saka H., Mitsuoka S., Fujimoto D., Nishino K., Horiike A., Daga H., Sone T., Yamamoto N., Nakagawa K. & Nakanishi Y. , Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). , Journal of Clinical Oncology, 38(8), 793-803, 2020.03.
52. Takada K., Yoneshima Y., Tanaka K., Okamoto I., Shimokawa M., Wakasu S., Takamori S., Toyokawa G., Oba T., Osoegawa A., Tagawa T., Oda Y., Nakanishi Y. & Mori M. , Clinical impact of skeletal muscle area in patients with non‑small cell lung cancer treated with anti‑PD‑1 inhibitors, Journal of Cancer Research and Clinical Oncology , 146(5), 1217-1225, 2020.05.
53. Yoshioka H., Kato T., Okamoto I., Tanaka H., Hida T., Seto T., Kiura K., Tian Y., Azuma H. & Yamamoto N. , Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3., Future Oncology , 16(4), 49-60, 2020.02.
54. Sato Y., Okamoto I., Kameyama H., Kudoh S., Saito H., Sanada M., Kudo N., Wakimoto J., Fujino K., Ikematsu Y., Tanaka K., Nishikawa A., Sakaguchi R. & Ito T. , Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors, Diagnostics, 10(11), 949, 2020.11.
55. Senan S., Okamoto I., Lee GW., Chen Y., Niho S., Mak G., Yao W., Shire N., Jiang H. & Cho BC. , Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. , Clinical Lung Cancer , 21(2), e84-e88, 2020.03.
56. Ando N., Tanaka K., Otsubo K., Toyokawa G., Ikematsu Y., Ide M., Yoneshima Y., Iwama E., Inoue H., Ijichi K., Tagawa T., Nakanishi Y. & Okamoto I. , Association of Mps one binder kinase activator 1(MOB1) expression with poor disease-survival in individuals with non-small cell lung cancer.
, Thoracic Cancer , 11(10), 2830-2839, 2020.10.
57. Ikematsu Y., Tanaka K., Toyokawa G., Ijichi K., Ando N., Yoneshima Y., Iwama E., Inoue H., Tagawa T., Nakanishi Y. & Okamoto I. , NEUROD1 is highly expressed in extensive-stage small cell lung cancer and promotes tumor cell migration., Lung Cancer, 146, 97-104
, 2020.08.
58. Shiraishi Y., Kishimoto J., Tanaka K., Sugawara S., Daga H., Hirano K., Azuma K., Hataji O., Hayashi H., Tachihara M., Mitsudomi T., Seto T., Nakagawa K., Yamamoto N. & Okamoto I. , Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer., Clinical Lung Cancer, 21(5), 472-476, 2020.09.
59. Tanaka K., Morita S., Ando M., Yokoyama T., Nakamura A., Yoshioka H., Ishiguro T., Miura S., Toyozawa R., Oguri T., Daga H., Ko R., Bessho A., Tachihara M., Iwamoto Y., Hirano K, Nakanishi Y., Nakagawa K., Yamamoto N. & Okamoto I. , A Randomized Phase III Study of Maintenance Therapy with　S-1 Plus Best Supportive Care Versus Best Supportive Care　After Induction Therapy with Carboplatin Plus S-1 for Advanced or Relapsed Squamous Cell Carcinoma of the Lung　(WJOG7512L), Cancer, 126(16), 3648-3656, 2020.08.
60. Otsubo K., Iwama E., Ijichi K., Kubo N., Yoneshima Y., Inoue H., Tanaka K., Osoegawa A., Tagawa T., Nakanishi Y. & Okamoto I. , Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis, Cancer Science, 111(7), 2482-2487 , 2020.07.
61. Tsuchiya-Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya K., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K., Nishikawa K., Kishimoto J., Nakanishi Y. & Okamoto I. , Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.

, The Oncologist, 25(6), 475-e891, 2020.06.
62. Iwama E., Goto Y., Murakami H., Tsumura S., Sakashita H., Mori Y., Nakagaki N., Fujita Y., Seike M., Bessho A., Ono M., Nishitsuji M., Akamatsu H., Morinaga R., Akagi T., Shimose T., Tokunaga S., Yamamoto N., Nakanishi Y., Sugio K. & Okamoto I. , Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
, The Oncologist, 25(4), 306-e618, 2020.04.
63. Iwama E., Sakai K., Hidaka N., Inoue K., Fujii A., Nakagaki N., Ota K., Toyozawa R., Azuma K., Nakatomi K., Harada T., Hisasue J., Sakata S., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I., Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors., Cancer , 126(1), 219-227, 2020.01.
64. Isamu Okamoto, Hiroshi Nokihara, Shogo Nomura, Seiji Niho, Shunichi Sugawara, Hidehito Horinouchi, Koichi Azuma, Yasuto Yoneshima, Haruyasu Murakami, Yukio Hosomi, Shinji Atagi, Tomohiro Ozaki, Atsushi Horiike, Yuka Fujita, Hiroaki Okamoto, Masahiko Ando, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa, Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial, JAMA Oncology. 2020 Mar 12;6(5):e196828., doi: 10.1001/jamaoncol.2019.6828. Online ahead of print., 2020.03, Importance: Few clinical trials have been specifically designed for elderly patients with advanced non-small cell lung cancer (NSCLC), and the anticipated increase in the number of such patients has prompted a search for new treatment options that provide a greater palliative benefit.

Objective: To determine whether treatment with carboplatin plus pemetrexed followed by pemetrexed maintenance is noninferior compared with docetaxel monotherapy with regard to overall survival (OS) for elderly patients with advanced nonsquamous NSCLC.

Design, setting, and participants: This open-label, multicenter, noninferiority phase 3 randomized clinical trial was conducted at 79 institutions in Japan. Cytotoxic chemotherapy-naive patients with advanced nonsquamous NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and age of 75 years or older were enrolled between August 2013 and February 2017. Data were analyzed from November 2018 to February 2019.

Interventions: Patients were randomized to receive either docetaxel monotherapy (60 mg/m2) every 3 weeks or 4 cycles of carboplatin (area under the curve of 5) plus pemetrexed (500 mg/m2) administered every 3 weeks followed by maintenance therapy with the same dose of pemetrexed for 3 weeks.

Main outcomes and measures: The primary end point was OS analyzed on an intention-to-treat basis with a noninferiority margin of 1.154 for the upper limit of the 95% CI of the hazard ratio (HR) estimated with a stratified Cox regression model.

Results: Of the 433 enrolled patients, 250 (57.7%) were male, and the median (range) age was 78 (75-88) years. The median OS was 15.5 months (95% CI, 13.6-18.4) in the docetaxel group (n = 217) and 18.7 months (95% CI, 16.0-21.9) in the carboplatin-pemetrexed group (n = 216), with a stratified HR for OS of 0.850 (95% CI, 0.684-1.056; P for noninferiority = .003). Progression-free survival was also longer in the carboplatin-pemetrexed group (unstratified HR, 0.739; 95% CI, 0.609-0.896). Compared with those in the docetaxel group, those in the carboplatin-pemetrexed had lower rates of leukopenia (60 of 214 [28.0%] vs 147 of 214 [68.7%]) and neutropenia (99 of 214 [46.3%] vs 184 of 214 [86.0%]) of grade 3 or 4 and of febrile neutropenia (9 of 214 [4.2%] vs 38 of 214 [17.8%]) and higher rates of thrombocytopenia (55 of 214 [25.7%] vs 3 of 214 [1.4%]) and anemia (63 of 214 [29.4%] vs 4 of 214 [1.9%]) of grade 3 or 4. Dose reductions were less frequent with carboplatin-pemetrexed.

Conclusion and relevance: Carboplatin-pemetrexed treatment followed by pemetrexed maintenance is a valid option for first-line treatment of elderly patients with advanced nonsquamous NSCLC..
65. Yonesaka K., Iwama E., Hayashi H., Suzuki S., Kato R., Watanabe S., Takahama T., Tanizaki J., Tanaka K., Takeda M., Sakai K., Azuma K., Chiba Y., Atagi S., Nishio K., Okamoto I. & Nakagawa K. , Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

, Scientific Reports , 9(1), 19501, 2019.01.
66. Yoshioka H., Shimokawa M., Seto T., Morita S., Yatabe Y., Okamoto I., Tsurutani J., Satouchi M., Hirashima T., Atagi S., Shibata K., Saito H., Toyooka S., Yamamoto N., Nakagawa K. & Mitsudomi T., Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.
, Annals of Oncology, 30(12), 1978-1984
, 2019.12.
67. Nishio M., Sugawara S., Atagi S., Akamatsu H., Sakai H., Okamoto I., Takayama K., Hayashi H., Nakagawa Y. & Kawakami T., Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).

, Clinical Lung Cancer , 20(6), 469-476 , 2019.07.
68. Hirashima T., Satouchi M., Hida T., Nishio M., Kato T., Sakai H., Imamura F., Kiura K., Okamoto I., Kasahara K., Uchida H., Vowler SL. & Mitsudomi T., Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

, Cancer Science , 110(9), 2884-2893, 2019.09.
69. Takada K., Toyokawa G., Yoneshima Y., Tanaka K., Okamoto I., Shimokawa M., Wakasu S., Haro A., Osoegawa A., Tagawa T., Oda Y., Nakanishi Y. & Mori M., 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer.

, Scientific Reports , 9(1), 13362, 2019.01.
70. Takada K., Shimokawa M., Tanaka K., Kohashi K., Haro A., Osoegawa A., Tagawa T., Azuma K., Okamoto I., Oda Y. & Mori M., Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.

, PLoS One , 14(6), e0217991 , 2019.06.
71. Kubo N., Harada T., Shiraishi Y., Nosaki K., Nakagaki N., Takeshita M., Ouchi H., Iwama E., Tanaka K., Okamoto I., Sasaki H. & Nakanishi Y., Identification of Genomic Alterations Acquired During Treatment with EGFR-TKIs in Non-small Cell Lung Cancer

, Anticancer Research , 39(2), 671-677, 2019.02.
72. Ohe Y., Imamura F., Nogami N., Okamoto I., Kurata T., Terufumi Kato T., Sugawara S., Ramalingam SS., Uchida H., Hodge R., Vowler SL., Walding A & Nakagawa K, Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
, Japanese Journal of Clinical Oncology , 49(1), 29-36, 2019.01.
73. Sugawara S., Nakagawa K., Yamamoto N., Nokihara H., Ohe Y., Nishio M., Takahashi T., Goto K., Maemondo M., Ichinose Y., Seto T., Sakai H., Gemma A., Imamura F., Shingyoji M., Saka H., Inoue A., Takeda K., Okamoto I., Kiura K., Morita S. & Tomohide Tamura T.*, Japanese Subgroup Analysis of a Phase III Study of S-1 versus Docetaxel in Non-Small Cell Lung Cancer Patients After Platinum-Based Treatment: EAST-LC Identification of Genomic Alterations Acquired During Treatment with EGFR-TKIs in Non-small Cell Lung Cancer

, International Journal of Clinical Oncology, 24(5), 485-493, 2019.05.
74. Takamori S., Takada K., Azuma K., Jogo Y., Shimokawa M., Toyokawa G., Hirai F., Tagawa T., Kawahara A, Akiba J, Okamoto I., Nakanishi Y., Oda Y. Hoshino T & Maehara Y., Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

, Annals of Surgical Oncology , 26(6), 1916-1924, 2019.06.
75. Matsubara T., Takada K., Azuma K., Takamori S., Toyokawa G., Haro A., Osoegawa A., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y., A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma

, Annals of Surgical Oncology , 26(6), 1925-1933, 2019.06.
76. Fukuda M., Kitazaki T., Ogawara D., Ichiki M., Mukae H., Riichiroh Maruyama, Nakagaki N., Shimada M., Ikeda T., Kishimoto J., Harada T., Seto T., Ebi N., Takayama K., Okamoto I., Ichinose Y. & Sugio K., Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer

, Lung Cancer , 132, 1-8 , 2019.06.
77. Cho BC., Chewaskulyong B., Lee KH., Dechaphunkul A., Sriuranpong V., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cheng Y., Cho EK., Voon PJ., Lee JS., Mann H., Saggese M., Reungwetwattana T., Ramalingam SS. & Ohe Y., Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset.

, Journal of Thoracic Oncology, 14(1), 99-106, 2019.01.
78. Nogami N., Nishio M., Okamoto I., Enatsu S., Suzukawa K., Takai H., Nakagawa K. & Tamura T., Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients.

, Respiratory Investigation, 57(1), 27-33, 2019.01.
79. Akamatsu H., Koh Y., Okamoto I., Fujimoto D., Bessho A., Azuma K., Morita S., Yamamoto N. & Nakagawa K. , Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study), Lung Cancer, 131, 128-133, 2019.05.
80. Senan S., Okamoto I., Lee GW., Chen Y., Niho S., Mak G., Yao W., Shire N., Jiang H. & Cho BC., Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.

, Clinical Lung Cancer, Dec 28: S1525-7304 (19) 30374-2, 2019.12.
81. Gray JE., Okamoto I., Sriuranpong V., Vansteenkiste J., Imamura F., Lee JS., Pang YK., Cobo M., Kasahara K., Cheng Y., Nogami N., Cho EK., Su WC., Zhang G., Huang X., Li-Sucholeiki X., Lentrichia B., Dearden S., Jenkins S., Saggese M., Rukazenkov Y. & Ramalingam SS., Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

, Clinical Cancer Research , 25(22), 6644-6652, 2019.11.
82. Ikematsu Y., Tanaka K., Yanagihara T., Liu R., Inoue H., Yoneshima Y., Ota K., Iwama E., Takata S., Hata K., Takahata Y., Wataya H., Nakanishi Y. & Okamoto I., Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
, Lung Cancer, 138, 58-64
, 2019.12.
83. Tsuchiya-Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya K., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K., Nishikawa K., Kishimoto J., Nakanishi Y. & Okamoto I. , Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.

, The Oncologist, 24, 1-7 , 2019.04.
84. Udagawa H., Akamatsu H., Tanaka K., Takeda M., Kanda S., Kirita K., Teraoka S., Nakagawa K., Fujiwara Y., Yasuda I., Okubo S., Shintani M., Kosloski MP., Scripture C., Tamura T. & Okamoto I. , Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
, Lung Cancer , 135, 145-150 (2019), 2019.09.
85. Yoneshima Y., Tanaka K., Shiraishi Y., Hata K., Watanabe H., Harada T., Otsubo K., Iwama E., Inoue H., Masuda S., Nakanishi Y. & Okamoto I., Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

, Lung Cancer , 130, 5-9 (2019), 2019.04.
86. Otsubo K., Sakai K., Takeshita M., Harada D., Azuma K., Ota K., Akamatsu H., Goto K., Horiike A., Kurata T., Nakagaki N., Nosaki K., Iwama E., Nakanishi Y., Nishio K. & Okamoto I., Genetic Profiling of Non–Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA

, The Oncologist, 24, ８, 1022-1026, 2019.08.
87. Takamori S., Takada K., Azuma K., Jogo Y., Kinoshita F., Kozuma Y., Matsubara T., Haratake N., Akamine T., Toyokawa G., Hirai F., Tagawa T., Okamoto I., Nakanishi Y., Kawahara A., Akiba J., Oda Y. & Maehara Y., Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer., Anticancer Research, 38(10), 5903-5907, 2018.04.
88. Takamori S., Takada .K, Toyokawa G., Azuma K., Shimokawa M., Jogo T., Yamada Y., Hirai F., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y. , PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer., Anticancer Rsearch , 38(10), 5897-5901
, 2018.04.
89. Kiura K., Imamura F., Kagamu H., Matsumoto S., Hida T., Nakagawa K., Satouchi M., Okamoto I., Takenoyama M., Fujisaka Y., Kurata T., Ito M., Tokushige K., Hatano B. & Nishio M. , Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset., Japanese Journal of Clinical Oncology , 48(4), 367-375, 2018.04.
90. Akamine T., Takada K., Toyokawa G., Kinoshita F., Matsubara T., Kozuma Y., Haratake N., Takamori S., Hirai F., Tagawa T., Okamoto T., Yoneshima Y., Okamoto I., Shimokawa M., Oda Y., Nakanishi Y. & Maehara Y. , Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers., Journal of Surgical Oncology, 27(1), 88-94, 2018.03.
91. Kato T., Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Tai L., Yu W., Khaznadar T., Tajima K., Shibata M., Seki A. & Yamamoto N. , Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): extended safety follow-up

, Drug Safety , 41(2), 229-237
, 2018.02.
92. Takamori S., Takada K., Azuma K., Jogo T., Shimokawa M., Toyokawa G., Hirai F., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y., Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients, Annals of Surgical Oncology, 38(10), 5903-5907, 2018.04.
93. Kiura K., Yoh K., Katakami N., Nogami N., Kasahara K., Takahashi T., Okamoto I., Cantarini M., Hodge R. & Uchida H. , Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples., Cancer Science, 109(4), 1177-1184, 2018.04.
94. Ryu S., Hayashi M., Aikawa H., Okamoto I., Fujiwara Y & Hamada A. , Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study., British Journal of Pharmacology , 175(1), 29-37, 2018.04.
95. Yabuuchi H., Kawanami S., Iwama E., Okamoto I., Kamitani T., Sagiyama K., Yamasaki Y. & Honda H. , Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups., Radiology , 286(2), 685-695
, 2018.02.
96. Reungwetwattana T., Nakagawa K., Cho BC., Cobo M., Cho EK., Bertolini A., Bohnet S., Zhou C., Lee KH., Nogami N., Okamoto I., Leighl N., Hodge R., McKeown A., Brown AP., Rukazenkov Y., Ramalingam SS. & Vansteenkiste J. , CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer., Journal of Clinical Oncology, 36, 33, 3290-3297, 2018.11.
97. 184. Soria JC., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee KH., Dechaphunkul A., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cho BC., Cheng Y., Cho EK., Voon PJ., Planchard D., Su WC., Gray JE., Lee SM., Hodge R., Marotti M., Rukazenkov Y., Ramalingam SS.; FLAURA , Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer., New England Journal of Medicine , 378, 2, 113-125, 2018.01.
98. Takamori S., Toyokawa G., Okamoto I., Takada K, Kinoshita F., Kozuma Y., Matsubara T., Haratake N., Akamine T., Mukae N., Hirai F., Tagawa T., Oda Y., Iwaki T., Iihara K., Nakanishi Y. & Maehara Y. , Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer., Anticancer Research , 38, 1, 553-557, 2018.04.
99. Akamatsu H., Katakami N., Okamoto I., Kato T., Kim YH., Imamura F., Shinkai M., Hodge RA., Uchida H. & Hida T. , Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial., Cancer Science, 109, 6, 1930-1938 , 2018.06.
100. Kimura S., Tanaka K., Harada T., Liu R., Shibahara D., Kawano Y., Nakanishi Y. & Okamoto I. , Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay., Cancer Science , 109, 11, 3657-3661, 2018.11.
101. Kimura S., Harada T., Ijichi K., Tanaka K., Liu R., Shibahara D., Kawano Y., Otsubo K., Yoneshima Y., Iwama E., Nakanishi Y. & Okamoto I. , Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer., Lung Cancer , 120, 98-107, 2018.06.
102. Tanaka K., Yanagihara T., Ikematsu Y., Inoue H., Ota K., Kashiwagi E., Suzuki K., Hamada N., Takeuchi A., Tatsugami K., Eto M., Ijichi K., Oda Y., Otsubo K., Yoneshima Y., Iwama E., Nakanishi Y. & Okamoto I. , Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget , 9, 55, 30587-30593 , 2018.07.
103. Otsubo K., Kishimoto J., Kenmotsu H., Minegishi Y., Ichihara E., Shiraki A., Kato T., Atagi S., Horinouchi H., Ando M., Kondoh Y., Kusumoto M., Ichikado K., Yamamoto N., Nakanishi Y. & Okamoto I. , Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non–small cell lung cancer with idiopathic pulmonary fibrosis, Clinical Lung Cancer, 19, 1, e5-e9, 2018.01.
104. Iwama E., Sakai K., Azuma K., Harada D., Nosaki K., Hotta K., Nishio M., Kurata T., Fukuhara T., Akamatsu H., Goto K., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I. , Exploration of resistance mechanisms for EGFR-TKIs based on plasma analysis by digital PCR and next-generation sequencing., Cancer Science , 109 , 3921-3933, 2018.04.
105. Anai S., Iwama E., Yoneshima Y., Otsubo K., Tanaka K., Nakanishi Y. & Okamoto I. , Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients, Lung Cancer, 126, 156-161, 2018.12.
106. Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya k., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K.,Nishikawa K.,Kishimoto J., Nakanishi Y. & 　Okamoto I. , Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer, Lung Cancer, 125, 136-141, 2018.11.
107. Yoneshima Y., Ijichi K., Anai S., Ota K., Otsubo K., Iwama E., Tanaka K., Oda Y., Nakanishi Y. & Okamoto I. , PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements., Lung Cancer, 118, 36-40, 2018.04.
108. Tanaka K., Isse K., Fujihira T., Takenoyama M,. Saunders L., Bheddah S., Nakanishi Y. & Okamoto I., Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.

, Lung Cancer, 115, 116-120, 2018.01.
109. Shibahara D., Tanaka K., Iwama E., Kubo N., Ota K., Azuma K., Harada T., Fujita J. Nakanishi Y. & Okamoto I., Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.

, Journal of Thoracic Oncology , 13, 7, 926-937, 2018.07.
110. Okamoto I., Morita S., Tashiro N., Imamura F., Inoue A., Seto T., Yamamoto N., Ohe Y., Nakagawa K. & Fukuoka M. , Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

, Lung Cancer, 117, 14-19, 2018.03.
111. Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay , Ota K., Harada T.*, Otsubo K., Fujii A., Tsuchiya Y., Tanaka K., Okamoto I. & Nakanishi Y., Oncotarget, 8, 42, 72127-72132, 2017.09.
112. Yoneshima Y., Morita S., Ando M., Miura S., Yoshioka H., Abe T., Kato T., Kondo M., Hosomi Y., Hotta K., Yamamoto N., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.* , Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer, Clinical Lung Cancer , 18, 1, 100-103, 2017.01.
113. Kawano Y., Iwama E., Tsuchihashi K., Shibahara D., Harada T., Tanaka K., Nagano O., Saya H., Nakanishi Y. & Okamoto I.* , CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment
, Lung Cancer, 72-78, 2017.11.
114. Tanaka K., Nosaki K., Otsubo K., Azuma K., Sakata S., Ouchi H., Morinaga R., Wataya H., Fujii A., Nakagaki N., Tsuruta N., Takeshita N., Iwama E., Harada T., Nakanishi Y. & Okamoto I.* , Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutation.
, Oncotarget, 8, 40, 68123-68130, 2017.09.
115. Hayashi H.*, Chiba Y., Sakai K., Fujita T., Yoshioka H., Sakai D., Kitagawa C., Naito T., Takeda K., Okamoto I., Mitsudomi T., Kawakami Y., Nishio K., Nakamura S., Yamamoto N. & Nakagawa K., A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study
, Clinical Lung Cancer, 2017.05.
116. Kato T.*, Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Tai L., Yu W., Khaznadar T., Tajima K., Shibata M., Seki A. & Yamamoto N. , Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): extended safety follow-up, Drug Safety, 2017.10.
117. Ryu S., Hayashi M., Aikawa H., Okamoto I., Fujiwara Y & Hamada A.* , Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study., British Journal of Pharmacology , 2017.10.
118. Yabuuchi H.*, Kawanami S., Iwama E., Okamoto I., Kamitani T., Sagiyama K., Yamasaki Y. & Honda H., Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.
, Radiology, 2017.10.
119. Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K. , HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

, Oncotarget 2016; 7(3), 3453-3460, 2016.03.
120. Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne P, Nakagawa K, Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
, Oncogene 2016; 35(7): , 878-886, 2016.07.
121. Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I, Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): an open-label, randomized, phase II trial


, Cancer 2016; 122 (7), 1050-1059, 2016.07.
122. Kawakami H, Okamoto I, MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.

, Gastric Cancer 2016, 687-695, 2016.03.
123. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M , Characteristics and overall survival of EGFR mutation-positive non-small cell lung
cancer treated with EGFR tyrosine kinase inhibitors: A Retrospective Analysis for
1,660 Japanese patients
, Japanese Journal of Clinical Oncology 2016, 462-467, 2016.05.
124. Sakata S, Saeki S, Okamoto I (Correspondence author), Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H , Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301

, Lung Cancer 2016, 41-45, 2016.09.
125. Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y , Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae , Journal of Thoracic Oncology 2016 , 1586-1590, 2016.09.
126. Yang J, Sequist L, Zhou C, Schuler M, Geater S, Mok T, Hu C, Yamamoto N, Feng J, O’Byrne K, Lu1 S, Hirsh V, Huang Y, Sebastian1 M, Okamoto I, Dickgreber N, Shah R, Märten1 A, Massey D, Wind S, Wu Y, Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-
positive lung adenocarcinoma: post-hoc analyses of the randomized LUX-Lung 3
and 6 trials

, Annals of Oncology 2016; 27(11), 2103-2110, 2016.11.
127. Nosaki K, Satouchi M, Kurata T, Yoshida T , Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka H, Yoshioka H, Watanabe K, Mizuno K, Seto T, Re-biopsy status among non-small cell lung cancer patients in Japan: a
retrospective study

, Lung Cancer 2016; Nov;101, 1-8, 2016.11.
128. Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K. , Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib


, ESMO open 2016; 1(4): e000063, 2016.11.
129. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K., FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

, Cancer Science, 1667-1676, 2016.11.
130. Ebi N, Tokunaga S, Itoh K, Okamoto I, Edakuni N, Fujii S, Watanabe K, Hayashi S, Maeyama T, Nakanishi Y., Multicenter cooperative observation study of idiopathic pulmonary fibrosis with non-small cell lung cancer

, World Journal of Respirology 2016; 6(1), 42-48, 2016.12.
131. Ogata H., Okamoto I., Yoshimoto G., Obara T., Ijichi K., Iwama E., Harada T., Akashi K. & Nakanishi Y. , Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
, Respiratory Investigation , 181-183, 2017.03.
132. Ikematsu Y., Yoneshima Y., Ijichi K., Tanaka K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.* , Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1
, Lung Cancer , 2017.07.
133. Yanagihara T., Tanaka K., Ota K., Kashiwagi E., Takeuchi A., Tatsugami K, Eto M, Nakanishi Y. & Okamoto I.* , Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment

, Annals of Oncology 28(8), 2038-2039, 2017.08.
134. Fukuda M.,* Shimada M., Kitazaki T., Nagashima S., Hashiguchi K., Ebi N., Takayama K., Nakanishi Y., Semba H., Harada T., Seto T., Okamoto I., Ichinose Y. & Sugio K., A phase I study of irinotecan for previously treated lung cancer patients with the 　
UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu

, Thoracic Cancer , 40-45, 2017.01.
135. 17. Takamori S, Toyokawa G*, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y. , Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-Small-Cell Lung Cancer.
ANTICANCER RESEARCH 37(8), 4223-4228 (2017)
, ANTICANCER RESEARCH 37(8), 4223--4228 (2017), 2017.08.
136. Hidaka N., Iwama E*., Kubo N., Harada T., Miyawaki K., Tanaka K., Okamoto I., Baba E., Akashi K., Sasaki H. & Nakanishi Y., Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer

, Lung Cancer, 75-82, 2017.06.
137. Iwama E., Sakai K., Azuma K., Harada T., Harada D., Nosaki K., Hotta K., Ohyanagi F., Kurata T., Fukuhara T., Akamatsu H., Goto K., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.*, Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations, Annals of Oncology, 136-141, 2017.01.
138. Iwama E., Goto Y., Murakami H., Harada T., Tsumura S., Sakashita H., Mori Y., Nakagaki N., Fujita Y., Seike M., Bessho A., Ono M., Okazaki A., Akamatsu H., Morinaga R., Ushijima S., Shimose T., Tokunaga S., Hamada H., Yamamoto N., Nakanishi Y., Sugio K. & Okamoto I.* , Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer
and a poor performance status (Lung Oncology Group in Kyushu 1401)
, Journal of Thoracic Oncology , 1161--1166 , 2017.12.
139. Okamoto I., Schuette H., Stinchcombe T., Rodorigues-Pereira J., Antonio B., Chen J., Liu J., John W.* & Zinner R. , Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
, Current Medical Research and Opinion , 937-941, 2017.05.
140. Otsubo K., Kishimoto J., Kenmotsu H., Minegishi Y., Ichihara E., Shiraki A., Kato T., Atagi S., Horinouchi H., Ando M., Kondoh Y., Kusumoto M., Ichikado K., Yamamoto N., Nakanishi Y. & Okamoto I.* , Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non–small cell lung cancer with idiopathic pulmonary fibrosis
, Clinical Lung Cancer, 2017.06.
141. Otsubo K., Nosaki K., Imamura C., Ogata H., Fujita A., Sakata S., Hirai F., Toyokawa G., Iwama E., Harada T., Seto T., Takenoyama T., Ozaki M., Mushiroda T., Inada M., Kishimoto J., Tsuchihashi K., Suina K., Nagano O., Saya H., Nakanishi Y. & Okamoto I.* , Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer



, Cancer Science 2017; 108(9): , 108, 9, 1843-1849, 2017.09.
142. Langer CJ., Hirsh V., Okamoto I., Lin FJ., Wan Y., Whiting S., Ong TJ., Renschler MF., Botteman MF., Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

, British Journal of Cancer 2015; 113(1): 20-29, 113, 1, 20-29, 2015.06.
143. Fijii A., Harada T., Iwama E., Ota K., Furuyama K., Ijichi K., Okamoto T., Okamoto I., Takayama K., Nakanishi Y., Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

, Cancer Genetics , 208, 5, 271-278, 2015.05.
144. Yonesaka K., Hirotani K., Kawakami H., Takeda M., Kaneda H., Sakai K., Okamoto I., Nishio K., Jänne P., Nakagawa K., Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

, Oncogene, 10, 11, 2015.05.
145. Abe H., Kawahara A., Azuma K., Taira T., Takase Y., Fukumitsu T., Murata K., Yamaguchi T., Akiba J., Ishii H., Okamoto I., Hoshino T., Takamori S., Kage M., Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinoma: A comparative study between small biopsy and excision samples
, Journal of Thoracic Oncology , 10, 5, 800-805, 2015.05.
146. Yoneshima Y., Okamoto I., Arima-Omori M., Kimura S., Hidaka-Fujimoto N., Iwama E., Harada T., Takayama K., Nakanishi Y., Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

, Investigational New Drugs , 33, 2, 510-512, 2015.04.
147. Takeda M., Okamoto I., Nakagawa K., Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
, Lung Cancer, 88, 1, 74-79, 2015.04.
148. Li H., Wang S., Takayama K., Harada T,, Okamoto I., Iwama E., Fujii A., Ota K., Hidaka N., Kawano Y., Nakanishi Y., Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Lung Cance
, Lung Cancer, 88, 1, 1-8, 2015.04.
149. Fujisaka Y., Kurata T., Tanaka K., Kudo T., Okamoto K., Tsurutani J., Kaneda H., Okamoto I., Namiki M., Kitamura C., Nakagawa K., Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.
, Investigational New Drugs , 33, 2, 380-388, 2015.04.
150. Yonesaka K., Satoh T., Ueda S., Yoshida T., Takeda M., Shimizu T., Okamoto I., Nishio K., Tamura T., Nakagawa K., Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer

, ANTICANCER RESEARCH, 35, 3, 1683-1689, 2015.03.
151. Okamoto I., Miyazaki M., Takeda M., Terashima M., Azuma K., Hayashi H., Kaneda H., Kurata T., Tsurutani J., Seto T., Hirai F., Konishi K., Sarashina A., Yagi N., Kaiser R., Nakagawa K., The tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a Phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

, Journal of Thoracic Oncology, 10, 2, 346-352, 2015.02.
152. Hayashi H., Arao T., Togashi Y., Kato H., Fujita Y., De Velasco MA., Kimura H., Matsumoto K., Tanaka K., Okamoto I., Ito A., Yamada Y., Nakagawa K., Nishio K., The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer
, Oncogene, 34, 2, 199-208, 2015.01.
153. Sakai K., Takeda M., Okamoto I., Nakagawa K., Nishio K., Multiple regulatory mechanism of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF promoter.
, Oncology Letters, 9, 1, 405-410, 2015.01.
154. Naito T., Seto T., Takeda K., Goto K., Okamoto I., Nakagawa K., Ohba T., Murakami H., Takahashi T., Yamanaka T., Yamamoto N., Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non–small-cell lung cancer., Lung Cancer, 86, 3, 339-343, 2014.12.
155. Kawakami H., Okamoto I., Yonesaka K., Okamoto K., Shibata K., Shinkai Y., Sakamoto H., Kitano M., Tamura T., Nishio K., Nakagawa K., The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells, Oncotarget, 5, 23, 11847-11856, 2014.12.
156. Li H, Takayama K, Wang S., Shiraishi Y., Gotanda K., Harada T., Furuyama K., Iwama E., Okamoto I, Nakanishi Y, Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression., Cancer Chemother Pharmacol. , 74, 6, 1297-1305, 2014.12.
157. Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., Yamamoto N., Hida T., Maemondo M., Nakagawa K., Nagase S., Okamoto I., Yamanaka T., Tajima K., Harada R., Fukuoka M., Yamamoto N., Erlotinib alone or with bevacizumab as a first-line therapy in patients with advanced non-squamous non–small-cell lung cancer harbouring epidermal growth factor receptor mutations (JO25567): a randomised phase II study
, Lancet Oncology, 15, 11, 1236-1244, 2014.10.
158. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., Matsumoto K., Takayama K., Takamori S., Kage M., Hoshimo T., Nakanishi Y., Okamoto I., Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer.
, Annal s of Oncology, 25, 10, 1935-1940, 2014.10.
159. Yoshida T., Zhang G., Smith MA., Lopez AS., Bai Y., Li J., Fang B., Koomen J., Rawal B., Fisher KJ., Chen AY., Kitano M., Morita Y., Yamaguchi H., Shibata K., Okabe T., Okamoto I., Nakagawa K., Haura EB., Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer.
, Clin Cancer Res., 20, 15, 4059-4074, 2014.08.
160. Okamoto K., Okamoto I., Takeda M., Kobayashi S., Takeda K., Nakamatsu K., Nishimura Y., Nakagawa K., A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
, Japanese Journal of Clinical Oncology, 44, 8, 743-748, 2014.08.
161. Murakami H., Yamanaka T., Seto T., Suigio K., Okamoto I., Sawa T., Hirashima T., Takeda K., Atagi S., Fukuoka M., Nakanishi Y., Nakagawa K., Yamamoto N., A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non–small-cell Lung Cancer: West Japan Oncology Group
, Cancer Science, 105, 8, 989-995, 2014.08.
162. Park KS., Raffeld M., Moon YW., Xi L, Bianco C., Pham T., Lee LC., Mitsudomi T., Yatabe Y., Okamoto I., Subramaniam D., Mok T., Rosell R., Luo J., Salomon DS., Wang Y., Giaccone G., CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance..
, Journal of Clinical Investigation, 124, 7, 3003-3015, 2014.07.
163. Okamoto I., Sakai K., Morita S., Yoshioka H., Kaneda H., Takeda K., Hirashima T., Kogure Y., Kimura T., Takahashi T., Atagi S., Seto T., Sawa T., Yamamoto M., Satouchi M., Okuno M., Nagase S., Takayama K., Tomii K., Maeda T., Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
, Oncotarget, 5, 8, 2293-2230, 2014.04.
164. Takeda K., Okamoto I., Nakagawa K., Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small cell lung cancer treated with gefitinib or erlotinib

, Journal of Thoracic Oncology, 9, 2, 200-204, 2014.02.
165. Hirsh V., Okamoto I., Hon JK., Page RD., Orshi J., Sakai H., Zhang H., Renschler MF., Socinski MA., Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer.

, Journal of Thoracic Oncology, 9, 1, 83-90, 2014.01.
166. Tsuya A., Kurata T., Tamiya A., Okamoto I., Ueda S., Sakai D., Sugimoto N., Matsumoto K., Goto I., Yamamoto N., Fukuoka M., Nakagawa K., A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
, Investigational New Drugs , 31, 6, 1568-1572, 2013.12.
167. Hironaka S., Ueda S., Yasui H., Nishina T., Tsuda M., Tsumura T., Sugimoto N., Shimodaira H., Tokunaga S., Moriwaki T., Esaki T., Nagase M., Fujitani K., Yamaguchi K., Ura T., Hamamoto Y., Morita S., Okamoto I., Boku N., Hyodo I., A Randomized, Open-label, Phase III Study Comparing Irinotecan with Paclitaxel for Treatment of Advanced Gastric Cancer Refractory to Combination Chemotherapy using Fluoropyrimidine plus Platinum: WJOG4007 Trial
, Journal of Clinical Oncology , 31, 35, 4438-4444, 2013.12.
168. Kawakami H., Okamoto I., Terao K., Sakai K., Suzuki M., Ueda S., Tanaka K., Kuwata K., Morita Y., Ono K., Nishio K., Nishimura Y., Doi K., Nakagawa K., Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma
, Cancer Medicine, 2, 6, 933-941, 2013.12.
169. Hayashi H., Okamoto I., Ueda S., Tanaka K., Okamoto K., Kawakami H., Nishina S., Takeda M., Fujisaka Y., Satoh T., Terao K., Nishimura Y., Doi K., Nakagawa K., Phase I Pharmacokinetic Study of S-1 Granules and Nedaplatin for Advanced Head and Neck Cancer
, Anticancer Reseach, 33, 12, 5699-5705, 2013.12.
170. Okamoto W., Yoshino T., Takahashi T., Okamoto I., Ueda S., Tsuya A., Boku N., Nishio K., Fukuoka M., Yamamoto N., Nakagawa K., A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
, Cancer Chemotherapy and Pharmacology, 72, 5, 1063-1071, 2013.11.
171. Li J., Bennett K., Stukaloy A., Fang B., Zhang G., Yoshida T., Okamoto I., Kim JY., Song L., Bai Y., Qian X., Rawal B., Schell M., Grebien F., Winter G., Rix U., Eschrich S., Koomen J., Superti-Furga G., Haura EB., Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
, 5, 9, 2013.11.
172. Okamoto I., Aoe K., Kato T., Hosomi Y., Yokoyama A., Imamura F., Hirashima T., Nishio M., Nogami N., Okamoto H., Saka H., Yamamoto N., Yoshizuka N., Sekiguchi R., Kiyosawa K., Nakagawa K., Tamura T., Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small cell lung cancer.
, Investigational New Drugs, 31, 5, 1275-1282, 2013.10.
173. Socinski MA., Okamoto I., Hon JK., Hirsh V., Dakhil SR., Page RD., Orsini J, Yamamoto N., Zhang H., Renschler MF., Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
, Annals of Oncology , 24, 9, 2390-2396, 2013.09.
174. Kawakami H., Okamoto I., Hayashi H., Taguri M., Morita S., Nakagawa K., Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

, European Journal of Cancer , 49, 14, 3003-3009, 2013.09.
175. Kawakami H., Okamoto I., Okamoto W., Takeda M., Ueda S., Kudo T., Nishina S., Fujisaka Y., Miyazaki M., Tsurutani J., Kurata T., Nakagawa K., Practical use of gemcitabine and cisplatin combination therapy as first-line treatment for Japanese patients with advanced biliary tract cancer
, Journal of Cancer Therapy , 4, 6, 1068-1073, 2013.08.
176. Satouchi M., Okamoto I., Sakai H., Yamamoto N., Ichinose Y., Ohmatsu H., Nogami N., Takeda K., Mitsudomi T., Kasahara K., Negoro S., Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
, Lung Cancer, 81, 1, 97-101, 2013.07.
177. Hasegawa Y., Okamoto I., Takezawa K., Miyazaki M., Tsurutani J., Yonesaka K., Morinaga R., Tsuya A., Terashima M., Kudoh T., Azuma K., Kurata T., Nishikawa T., Fukuoka M., Nishimura T., Nakagawa K., A phase I study of S-1with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

, Investigational New Drugs., 31, 3, 599-604, 2013.06.
178. Kogure Y., Ando M., Saka H., Chiba Y., Yamamoto N., Asami K., Hirashima T., Seto T., Nagase S., Otsuka K., Yanagihara K., Takeda K., Okamoto I., Aoki T., Takayama K., Yamasaki M., Kudoh S., Katakami N., Miyazaki M., Nakagawa K., Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of West Japan Oncology Group (WJOG) Study 3906L.
, Journal of Thoracic Oncology, 8, 6, 753-758, 2013.06.
179. Urata Y., Okamoto I., Takeda M., Hattori Y., Okuno K., Shimada T., Kurata T., Kaneda H., Miyazaki M., Terashima M., Tanaka K., Morita S., Nakagawa K., Negoro S., Satouchi M., Phase II study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naïve patients with advanced nonsquamous non–small cell lung cancer.
, Cancer, 119, 12, 2275-2281, 2013.06.
180. Hayashi H., Okamoto I., Taguri M., Morita S., Nakagawa K., Postprogression survival in patients with advanced non-small cell lung cancer who receive second- or third-line chemotherapy

, Clinical Lung Cancer, 2013.05.
181. Yoshioka H., Okamoto I., Morita S., Ando M, Takeda K., Seto T., Yamamoto N., Saka H., Atagi S., Hirashima T., Kudoh S., Satouchi M., Ikeda N., Iwamoto Y., Sawa T., Nakanishi Y., Nakagawa K., Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer: updated results of the West Japan Oncology Group LETS study
, Annals of Oncology, 24, 5, 1326-1331, 2013.05.
182. Ogi S., Fujita H., Kashihara M., Yamamoto C., Sonoda K., Okamoto I., Nakagawa K., Ohdo S., Tanaka Y., Kuwano M., Ono M., Sorting nexin2-mediated membarne trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.
, Cancer Science, 104, 5, 573-583, 2013.05.
183. Takeda K., Okamoto I., Nakagawa K., Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.
, Journal of Thoracic Oncology , 8, 5, 654-657, 2013.05.
184. Hayashi H., Tsurutani J., Satoh T., Masuda N., Okamoto W., Morinaga R., Terashima M., Miyazaki M., Okamoto I., Nishida Y., Tominaga S., Tokunaga Y., Yamaguchi M., Sakamoto J., Nakayama T., Nakagawa K., Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.

, Breast Cancer , 20, 2, 131-136, 2013.04.
185. Kiyota H., Okamoto I., Takeda M., Daga H., Naito T., Miyazaki M., Okada H., Hayashi H., Tanaka K., Terashima M., Azuma K., Murakami H., Takeda K., Yamamoto N., Nakagawa K., Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung .

, Cancer Chemotherapy and Pharmacology, 71, 4, 859-865, 2013.04.
186. Socinski MA., LangerCJ., Okamoto I., Hon JK., Hirsh V., Dakhil SR., Page RD., Orsini J., Zhang H., Renschler MF., Safety and Efficacy of Weekly nab®-Paclitaxel in Combination with Carboplatin as First-line Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer.

, Annals of Oncology , 24, 2, 314-321, 2013.02.
187. Kawakami H., Okamoto I., Arao T., Okamoto W., Matsumoto K., Taniguchi H., Kuwata K., Yamaguchi H., Nishio K., Nakagawa K., Yamada Y., MET amplification as a potential therapeutic target in gastric cancer.
, Oncotarget , 4, 1, 9-17, 2013.01.
188. Okamoto I., Arao T., Miyazaki M., Satoh T., Okamoto K., Tsunoda T., Nishio K., Nakagawa K., Clinical Phase I Study of Elpamotide, a Peptide Vaccine for VEGFR 2, in Patients with Advanced Solid Tumors.

, 103, 12, 2135-2138, 2012.12.
189. Takeda M., Okamoto I., Sakai K., Kawakami K., Nishio K., Nakagawa K., Clinical outcome for EML4-ALK–positive patients with advanced non–small cell lung cancer treated with first-line platinum-based chemotherapy

, Annals of Oncology, 23, 11, 2931-2936, 2012.11.
190. Takeda M., Okamoto I., Sakai K., Kawakami K., Nishio K., Nakagawa K., Clinical outcome for EML4-ALK–positive patients with advanced non–small cell lung cancer treated with first-line platinum-based chemotherapy

, Annals of Oncology, 23, 11, 2931-2936, 2012.11.
191. Tanizaki J., Okamoto I., Okabe T., Sakai K., Tanaka K., Hayashi H., Kaneda H., Takezawa K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Nakagawa K., Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer., 18, 22, 6219-6226, 2012.11.
192. Hayashi H., Okamoto I., Kimura H., Sakai K., Nishimura Y., Nishio K., Nakagawa K., Clinical Outcome of Thoracic Radiotherapy for Locally Advanced NSCLC with EGFR Mutations or EML4-ALK, 32, 10, 4533-4537, 2012.10.
193. Takeda M., Okamoto I., Yamanaka T., Nakagawa K., Nakanishi Y., Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L), BMC cancer, 12, 1, 327, 2012.08.
194. Okamoto W., Okamoto I., Arao T., Kuwata K., Hatashita E., Yamaguchi H., Sakai K., Yanagihara K., Nishio K., Nakagawa K., Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification.

, Molecular Cancer Therapeutics, 11, 1557-1564, 2012.07.
195. Okamoto I., Yamamoto N., Kubota K., Ohe Y., Nogami N., Murakami H., Yamaha H., Ono K., Nakagawa K., Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.

, Investigational New Drugs, 30, 1132-1137, 2012.06.
196. Socinski M., Bondarenko I., Karaseva N., Makhson A., Vynnychenko I., Okamoto I., Hon J., Hirsh V., Bhar P., Zhang H., Iglesias J., Renschler M., Weekly nab-Paclitaxel in Combination with Carboplatin vs Solvent-based Paclitaxel Plus Carboplatin as First-line Therapy in Patients With Advanced Non-small Cell Lung Cancer: Final Results of a Phase 3 Trial

, Journal of Clinical Oncology, 30, 17, 2055-2062, 2012.06.
197. Takeda M., Okamoto I., Tsurutani J., Oiso N., Kawada A., Nakagawa K., Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC

, Japanese Journal of Clinical Oncology, 42, 6, 528-533, 2012.06.
198. Hayashi H., Okamoto I., Morita S., Taguri M., Nakagawa K., Postprogression survival for first-line chemotherapy of patients with advanced non–small cell lung cancer

, Annals of Oncology, 23, 6, 1537-1541, 2012.06.
199. Sakai K., Okamoto I., Takezawa K., Hirashima T., Kaneda H., Takeda M., Matsumoto K., Kimura H., Fujita Y., Nakagawa K., Arao T., Nishio K., A novel mass spectrometry–based assay for diagnosis of EML4-ALK–positive non–small cell lung cancer

, Journal of Thoracic Oncology, 7, 913-918, 2012.05.
200. Okamoto I., Shimizu T., Miyazaki M., Tsurutani J., Ichikwa Y., Terashima M., Takeda M., Fumita S., Ohki E., Kimura N., Hashimoto J., Nakagawa K., Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
, Investigational New Drugs, 30, 639-646, 2012.04.
201. Okamoto I., Yoshioka H., Takeda K., Satouchi M., Yamamoto N., Seto T., Kasahara K., Miyazaki M., Kitamura R., Ohyama A., Hokoda N., Nakayama H., Yoshihara E., Nakagawa K., Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced non–small cell lung cancer
, Journal of Thoracic Oncology, 7, 427-433, 2012.02.
202. Tanizaki J., Okamoto I., Takezawa K., Sakai K., Azuma K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Janne PA., Nakagawa K., Combined effect of ALK and MEK inhibitor in EML4-ALK-positive non-small-cell lung cancer cells
, British Journal of Cancer , 106, 763-767, 2012.02.
203. Tanaka K., Arao T., Tamura D., Aomatsu K., Furuta K., Matsumoto K., Kaneda H., Kubo K., Fujita Y., KimuraH., Yanagihara K., Yamada Y., Okamoto I., Nkagawa K., Nishio K., SRPX2 is Novel Chondroitin Sulfate Proteoglycan That is Overexpressed in Gastrointestinal Cancer

, PLoS One , 7, 2012.01.
204. Azuma K., Okamoto I., Kawahara A., Taira T., Nakanishima K., Hattori S., Kinoshita T., Takeda M., Nakagawa K., Takamori S., Kuwano M., Ono M., Kage M., Association of the expression of mutant EGFR protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

, Journal of Thoracic Oncology , 7, 122-127, 2012.01.
205. Okamoto K., Okamoto I., Hatashita E., Kuwata K., Yamaguchi H., Kita A., Yamanaka K., Ono M., Nakagawa K., Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin, Molecular Cancer Therapeutics, 11, 204-213, 2012.01.


Unauthorized reprint of the contents of this database is prohibited.

Copyright © 2006, Kyushu University. All rights reserved.